共 302 条
[1]
Wang T(2010)Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116 1518-1525
[2]
Nelson RA(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[3]
Bogardus A(2013)Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 69 151-159
[4]
Grannis FW(2012)Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions Crit Rev Oncol Hematol 84 47-58
[5]
Schiller JH(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[6]
Harrington D(2008)Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272-7283
[7]
Belani CP(2009)Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 3836-3841
[8]
Langer C(2012)Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours Br J Cancer 107 1277-1285
[9]
Sandler A(2008)Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543-3551
[10]
Krook J(2012)Pharmacokinetic (PK) analysis of coadministration of axitinib and pemetrexed/cisplatin (pem/cis) in patients with non–small cell lung cancer (NSCLC) [abstract PI-69] Clin Pharmacol Ther 91 S33-382